Conditions: HER2-positive Breast Cancer; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
Interventions: Biological: pNGVL3-hICD vaccine; Biological: sargramostim; Other: flow cytometry; Other: immunologic technique; Other: immunoenzyme technique; Genetic: protein expression analysis; Procedure: biopsy
Sponsors: University of Washington; National Cancer Institute (NCI)
Active, not **RECRUITING NOW**
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.